PUBLISHER: The Business Research Company | PRODUCT CODE: 2098811
PUBLISHER: The Business Research Company | PRODUCT CODE: 2098811
Human papillomavirus (HPV) genotyping panels are comprehensive diagnostic testing systems developed to detect and distinguish multiple HPV genotypes from a single biological specimen through the analysis of unique genetic markers. These panels allow the concurrent identification of a wide range of HPV types, including those linked to different levels of clinical significance, by utilizing multiplex viral DNA analysis techniques. HPV genotyping panels support accurate classification and risk assessment of HPV infections for clinical and diagnostic purposes.
The primary product types of Human Papillomavirus (HPV) genotyping panels include high-risk Human Papillomavirus (HPV) genotyping panels, low-risk Human Papillomavirus (HPV) genotyping panels, and comprehensive Human Papillomavirus (HPV) genotyping panels. High-risk HPV genotyping panels are molecular diagnostic tests designed to identify oncogenic HPV strains linked to cervical cancer and other HPV-associated disorders, supporting early detection and patient risk assessment. These panels are based on technologies such as polymerase chain reaction (PCR)-based methods, deoxyribonucleic acid (DNA) microarrays, next-generation sequencing, and hybridization techniques. Their applications span clinical diagnostics, research activities, epidemiological investigations, and other uses, while end users include hospitals and clinics, diagnostic laboratories, research organizations, and others.
Tariffs are influencing the human papillomavirus (HPV) genotyping panels market by raising the expenses of imported diagnostic reagents, sequencing kits, and laboratory instruments that are essential for molecular testing workflows. This is resulting in increased operational expenditure for diagnostic laboratories and healthcare providers, especially in import dependent regions including Asia-Pacific and Latin America. Market segments such as next generation sequencing based panels and comprehensive HPV genotyping solutions are experiencing the greatest impact due to their dependence on advanced imported technologies and components. However, tariffs are also promoting domestic production of diagnostic kits, strengthening regional manufacturing collaborations, and broadening supply chain diversification, thereby enhancing long-term resilience and improving accessibility of HPV testing solutions.
The human papillomavirus (HPV) genotyping panels market size has grown steadily in recent years. It will grow from $1.79 billion in 2025 to $1.84 billion in 2026 at a compound annual growth rate (CAGR) of 2.7%. The growth in the historic period can be attributed to the increasing incidence of HPV infections worldwide, growing awareness of cervical cancer screening initiatives, expansion of molecular diagnostic laboratory infrastructure, rise in government-supported screening programs, and increasing adoption of PCR-based diagnostic methods.
The human papillomavirus (HPV) genotyping panels market size is expected to see steady growth in the next few years. It will grow to $2.07 billion in 2030 at a compound annual growth rate (CAGR) of 3.0%. The growth in the forecast period can be attributed to increasing demand for personalized and precision diagnostics, rising adoption of next-generation sequencing technologies, expanding use of AI-enabled diagnostic interpretation systems, growing focus on early cancer detection and preventive healthcare, and increasing investment in advanced molecular diagnostic platforms. Major trends in the forecast period include rising adoption of next-generation sequencing-based HPV genotyping platforms, growing use of multiplex PCR assays for high-throughput viral detection, increasing demand for comprehensive cervical cancer screening solutions, expanding integration of digital pathology with molecular diagnostics, and growing shift toward automated and high-sensitivity diagnostic workflows.
The rising prevalence of HPV-related cancers is expected to propel the growth of the human papillomavirus (HPV) genotyping panels market going forward. HPV-related cancers refer to malignancies caused by persistent infection with high-risk human papillomavirus strains, including cervical cancer, oropharyngeal cancer, anal cancer, vulvar cancer, and penile cancer. The prevalence of HPV-related cancers is rising due to increasing rates of HPV infection globally and growing aging populations with higher cancer susceptibility. HPV genotyping panels support the management of rising HPV-related cancer prevalence by accurately identifying specific high-risk HPV strains, enabling early diagnosis, guiding targeted treatment decisions, and facilitating population-based cervical cancer screening programs. For instance, in 2025, according to the National Institutes of Health, a US-based government agency, globally, cervical cancer accounted for an estimated 662,044 new cases and 348,709 deaths in 2022, and these figures are projected to rise significantly, with cases increasing by 56.8% and deaths by 80.7% by 2050. Therefore, the rising prevalence of HPV-related cancers is driving the growth of the human papillomavirus (HPV) genotyping panels market.
The rising healthcare expenditure is expected to propel the growth of the human papillomavirus (HPV) genotyping panels market going forward. Healthcare expenditure refers to the total spending on health services, including preventive care, diagnostic services, treatments, and healthcare infrastructure. The rise in healthcare expenditure is increasing due to expanding access to healthcare services and growing government investments in public health systems. HPV genotyping panels benefit from rising healthcare expenditure by enabling healthcare providers to invest in advanced molecular diagnostic tools, expand screening programs, improve laboratory infrastructure, and enhance early detection and management of HPV-related diseases. For instance, in April 2025, according to the American Medical Association, a US-based professional association, in 2023, health spending in the U.S. rose by 7.5%, reaching $4.9 trillion, or $14,570 per person, marking a notable increase compared to the 4.6% growth recorded in 2022. Therefore, the rising healthcare expenditure is driving the growth of the human papillomavirus (HPV) genotyping panels market.
Leading companies operating in the human papillomavirus (HPV) genotyping panels market are focusing on developing advanced solutions, such as self-collection-based diagnostic solutions to expand screening accessibility, improve early detection rates, and enhance patient compliance in cervical cancer prevention programs. Self-collection-based diagnostic solutions refer to testing approaches that allow patients to collect their own biological samples, which are then analyzed using molecular assays for accurate detection and genotyping of HPV infections. For example, in May 2024, F. Hoffmann-La Roche Ltd., a Switzerland-based healthcare company, received FDA approval for its cobas HPV Self-Collection Solution, which is integrated with the cobas HPV test. The solution enables the detection of 14 high-risk HPV genotypes, including HPV 16 and HPV 18, and allows patients to self-collect samples within healthcare settings. This innovation improves access to screening, particularly for underserved populations, and supports broader adoption of HPV testing in routine clinical practice.
Major companies operating in the human papillomavirus (HPV) genotyping panels market are F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermo Fisher Scientific Inc., Danaher Corporation, Becton Dickinson and Company, Hologic Inc., Revvity Inc., QIAGEN N.V., DiaSorin S.p.A., BGI Group, Seegene Inc., Fujirebio, Daan Gene Co. Ltd., Sansure Biotech Inc., Hybribio Limited, Tellgen Corporation, Mylab Discovery Solutions Pvt. Ltd., Molbio Diagnostics Pvt. Ltd., 3B BlackBio Dx Limited, Jiangsu Macro & Micro-Test Med-Tech Co. Ltd., Mikrogen Diagnostik, GeneFirst Limited.
North America was the dominant region in the human papillomavirus (HPV) genotyping panels market in 2025. Asia-Pacific is expected to be the rapidly expanding regionin the forecast period. The regions covered in the human papillomavirus (HPV) genotyping panels market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the human papillomavirus (HPV) genotyping panels market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The human papillomavirus (HPV) genotyping panels market consists of sales of partial genotyping panels, isothermal amplification HPV genotyping kits, line probe assay HPV genotyping kits, and lyophilized HPV genotyping kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The human papillomavirus (HPV) genotyping panels market research report is one of a series of new reports from The Business Research Company that provides human papillomavirus (HPV) genotyping panels market statistics, including human papillomavirus (HPV) genotyping panels industry global market size, regional shares, competitors with a human papillomavirus (HPV) genotyping panels market share, detailed human papillomavirus (HPV) genotyping panels market segments, market trends and opportunities, and any further data you may need to thrive in the human papillomavirus (HPV) genotyping panels industry. This human papillomavirus (HPV) genotyping panels market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Human Papillomavirus (HPV) Genotyping Panels Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses human papillomavirus (hpv) genotyping panels market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for human papillomavirus (hpv) genotyping panels ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The human papillomavirus (hpv) genotyping panels market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.